Neumora Therapeutics, Inc. NMRA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2023 · data as of November 13, 2026
Neumora Therapeutics, Inc. (NMRA) is a healthcare company listed in the US with a market value of about $81M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -67%.
About Neumora Therapeutics
Neumora Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2023. It was profitable in 0 of the last 4 years in our data. Its share count rose by 501% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net income | -$237M | -$244M | -$236M | -$131M |
| Free cash flow | — | — | -$163M | -$115M |
| EPS (diluted) | $-1.45 | $-1.53 | $-3.63 | $-4.81 |
| Net margin | — | — | — | — |
| ROIC | -87.0% | -72.0% | -42.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Neumora Therapeutics pay a dividend?
Not currently.
Is Neumora Therapeutics a good stock to buy?
We do not give buy or sell advice. Neumora Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.